Detection of CTC and ctDNA in the Diagnosis of Metastasis in Gastric Cancer
NCT ID: NCT05208372
Last Updated: 2022-01-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2022-01-01
2024-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Detection of Plasma Circulating Tumor DNA in Gastric Cancer
NCT05027347
Potential Clinical Utilities of Circulating Tumor DNA in Advanced HER2 Negative Gastric Cancer
NCT05513144
ctDNA Screening in Advanced HER2 Positive Gastric Cancer
NCT04520295
ctDNA-MRD Monitoring After Resection in Gastric Cancer
NCT06893133
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Hepatobiliary Cancer Malignancies
NCT04835675
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Laparotomy group
Patients who undergo radical laparotomy for gastric cancer.
CTC test
Circulating tumor cells test of ascites and blood for patients with gastric cancer.
ctDNA test
Circulating tumor DNA test of ascites and blood for patients with gastric cancer.
Laparoscopy group
Patients who undergo laparoscope-assisted radical gastrectomy for gastric cancer.
CTC test
Circulating tumor cells test of ascites and blood for patients with gastric cancer.
ctDNA test
Circulating tumor DNA test of ascites and blood for patients with gastric cancer.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CTC test
Circulating tumor cells test of ascites and blood for patients with gastric cancer.
ctDNA test
Circulating tumor DNA test of ascites and blood for patients with gastric cancer.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Gastric cancer is determined by more than 2 pathologists.
3. Patients with Borrmann III/IV gastric cancer.
Exclusion Criteria
2. Patients who complicate with other serious heart and lung diseases.
3. Patients who receive preoperative neoadjuvant chemotherapy.
18 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Hospital of China Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kai Li
Deputy Director of surgical Oncology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kai Li, MD
Role: STUDY_DIRECTOR
First Hospital of China Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
First Hospital of Jinzhou Medical University
Jinzhou, Liaoning, China
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yubin Wang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FirstHCMU_CTC_ctDNA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.